Presbyopia currently exhibits a strong pipeline with nine drug candidates, P&S Intelligence
The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation.
Access Report Summary with Detailed TOC on “Presbyopia” Therapeutics Pipeline Analysis, 2018 - Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments” at: https://www.psmarketresearch.com/market-analysis/presbyopia-therapeutics-pipeline-analysis
Insights on pipeline segments
Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.
Positive clinical results of presbyopia drug candidates
Various pharmaceutical companies are developing drug candidates for the treatment of presbyopia, which have shown positive results in different stages of development. For instance, UNR844 showed a statistically significant difference to placebo in distant corrected near vision at all time points measured (from day 8) in the Phase I/II, placebo-controlled, proof-of-concept study carried out in 50 patients daily for 90 days with topical UNR844 and in 25 patients with placebo. At day 90, 82% of participants treated with UNR844 had 20/40 near vision (or 0.30 LogMAR) versus 48% in the placebo group. Near vision of 20/40 allows the majority of near vision tasks in most people.
Novel delivery systems and patented technologies for Presbyopia
Various pharmaceutical companies are involved in manufacturing drugs for the treatment of presbyopia. In January 2017, Alcon, the eye care division of Novartis AG, launched AcrySof IQ PanOptix Toric intraocular lens for presbyopia. The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant achievement in presbyopia treatment. Most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia.
Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.
Presbyopia pipeline analysis